IBIO SEC Filings: 8-K, 10-Q, S-3 & 424B – iBio

Financials

TYPE

HEADLINE

FILED AT

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Aug 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Feb 10, 2026

10-Q/A

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Nov 17, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Sep 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

iBio, Inc. Announces Voting Results and Stockholder Approval from its 2026 Annual Meeting

Oct 19, 2026

8-K

iBio Highlights Data from Non-human Primate Study Supporting IBIO-610 Muscle Preservation in Combination with GLP-1 Therapy

Oct 13, 2026

8-K

iBio Highlights Breakthrough Antibody Portfolio for Obesity and Cardiometabolic Diseases

Sep 14, 2026

8-K

iBio Reports Fiscal Year 2026 Financial Results and Corporate Pipeline Progress

Aug 28, 2026

8-K

iBio Appoints Endocrinologist Molly Carr, M.D., as Chief Medical Officer

Aug 4, 2026

8-K

iBio, Inc. Announces Date for 2026 Annual Meeting of Stockholders and Revised Deadlines for Stockholder Proposals

Jul 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 11,061,738

Apr 29, 2026

424B5

March 2026 ATM | Offering amount: $100,000,000 | Bank: Jefferies LLC

Mar 6, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 11,061,738 | Bank: Leerink Partners LLC

Feb 9, 2026

424B5

REGISTERED OFFERING

Aug 21, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Leerink Partners, LifeSci Capital, Oppenheimer & Co.

Aug 18, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 11,253,370 | Share price: $0.86 | Warrants amount: 11,253,370.86

Jun 24, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-3

February 2026 SHELF and ATM

Feb 27, 2026

S-3

SHARE RESALE REGISTRATION

Jan 30, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Jan 22, 2026

S-3

SHARE RESALE REGISTRATION | Shares amount: 11,253,370 | Share price: $1.03 | Warrants amount: 11,253,370 .86

Jun 13, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

May 7, 2025

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Mar 3, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Sep 4, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Aug 20, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 6, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 10, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 26, 2023

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 16, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Stoner Elizabeth (Reporting)

Oct 15, 2026

Kropotova Alexandra (Reporting)

Oct 15, 2026

Arkowitz David (Reporting)

Oct 15, 2026

Clark William D (Reporting)

Oct 15, 2026

Parada Antonio Bernardino Guimaraes (Reporting)

Oct 15, 2026

Sender Gary (Reporting)

Oct 15, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 9, 2026

CORRESP

Form CORRESP - Correspondence

Mar 4, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 4, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 10, 2026

CORRESP

Form CORRESP - Correspondence

Feb 5, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 5, 2026

iBio, Inc. IBIO · SEC Filings